Skip to content
AnalystLens

Medtronic plc 8-K Report, Regulation FD Disclosure (Mar 24, 2026)

Reports
Regulation FD
Filing Date
Filed March 24, 2026
Period End
March 24, 2026
Security
MDT
In the record · 2016–202610-K1110-Q328-K120

MDT filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 120 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Mar ’19Mar ’19
  2. Leadership change8-K · Jun ’21Jun ’21
  3. Leadership change8-K · May ’25May ’25

01—Abstract

Summary

Summary of the 8-K filed March 24, 2026. Cited figures are marked; the original filing is the authoritative source.

Medtronic plc (MDT) announced an important regulatory milestone for its consolidated subsidiary, MiniMed Group, Inc. The U.S. Food and Drug Administration (FDA) has granted clearance for the MiniMed Flex™, a next-generation insulin pump.

This clearance arrived several months ahead of schedule, enabling an earlier commercial launch for this significant product in the diabetes management market. The development of the MiniMed Flex was partially funded by Blackstone, and under their agreement, Medtronic will incur a one-time charge of $157 milliona in the fourth quarter of fiscal year 2026, impacting reported EPS by approximately $0.08 per share. This charge relates to future payments to Blackstone based on sales performance during the initial two years post-launch.

Additionally, the previously disclosed initial public offering (IPO) of 10% of MiniMed will contribute an additional $0.04b per share dilution to Medtronic shareholders in the fourth quarter of fiscal year 2026. Consequently, Medtronic has revised its non-GAAP EPS guidance for fiscal year 2026 downward to a range of $5.50 to $5.54, from the previous $5.62 to $5.66 range. The company's long-term outlook for fiscal year 2027, projecting high single-digit EPS growth, remains unchanged.

02—Key points

Key Highlights

  1. FDA clearance for MiniMed Flex™ insulin pump received ahead of schedule.
  2. Earlier commercialization expected for the new smartphone-controlled insulin pump.
  3. A one-time charge of $157 million to be recognized in Q4 FY2026 related to MiniMed Flex™ development funding.
  4. This charge is expected to reduce Q4 FY2026 EPS by approximately $0.08 per share.
  5. Additional $0.04 per share dilution in Q4 FY2026 from the MiniMed IPO.
  6. Revised FY2026 non-GAAP EPS guidance to $5.50-$5.54, down from $5.62-$5.66.
  7. FY2027 EPS growth guidance of high single digits remains unchanged.

03—Questions

Frequently Asked Questions

  1. What is the significance of the FDA clearance for MiniMed Flex™?

    The FDA clearance for MiniMed Flex™ is significant because it allows for an earlier-than-anticipated commercial launch of a new, advanced insulin pump. This product is a key offering for Medtronic's diabetes management segment and is expected to drive future revenue.

  2. What is the financial impact of the MiniMed Flex™ clearance and development agreement?

    Medtronic will recognize a one-time charge of $157 million in the fourth quarter of fiscal year 2026 related to future payments to Blackstone for development funding. This charge is expected to reduce reported EPS by approximately $0.08 per share in that quarter.

  3. Why has Medtronic lowered its fiscal year 2026 EPS guidance?

    The EPS guidance for fiscal year 2026 has been lowered due to the combination of the one-time charge related to the MiniMed Flex™ development agreement and the ongoing dilutive impact from the MiniMed IPO. These factors are expected to reduce the full-year non-GAAP EPS to a range of $5.50 to $5.54.

  4. Will the MiniMed-related charges affect Medtronic's performance in fiscal year 2027?

    The filing states that the arrangements related to MiniMed, specifically the one-time charge to Blackstone, are not expected to impact Medtronic's results for fiscal year 2027. The company's guidance for high single-digit EPS growth in FY2027 remains consistent.

04—Continue

← View all 8-K filings